155 related articles for article (PubMed ID: 38823486)
1. Stereotactic body radiation therapy for primary renal cell carcinoma: A review on behalf of the CC-AFU.
Bentahila R; Bensalah K; Benziane-Ouaritini N; Barthelemy P; Rioux-Leclerc N; Correas JM; Belhomme S; Bigot P; Sargos P
Fr J Urol; 2024 May; 34(7-8):102660. PubMed ID: 38823486
[TBL] [Abstract][Full Text] [Related]
2. The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma.
Barbour AB; Kirste S; Grosu AL; Siva S; Louie AV; Onishi H; Swaminath A; Teh BS; Psutka SP; Weg ES; Chen JJ; Zeng J; Gore JL; Hall E; Liao JJ; Correa RJM; Lo SS
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509333
[TBL] [Abstract][Full Text] [Related]
3. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
4. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma.
Zalay O; Mehra P; Pereira I; Malone J; Malone S
World J Urol; 2024 Jan; 42(1):52. PubMed ID: 38244135
[TBL] [Abstract][Full Text] [Related]
5. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
[TBL] [Abstract][Full Text] [Related]
6. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative radiotherapy for primary renal cell carcinoma.
Yang DX; Kwon YS; Timmerman R; Hannan R
Clin Transl Radiat Oncol; 2024 Jan; 44():100705. PubMed ID: 38073715
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
Rühle A; Andratschke N; Siva S; Guckenberger M
Clin Transl Radiat Oncol; 2019 Sep; 18():104-112. PubMed ID: 31341985
[TBL] [Abstract][Full Text] [Related]
10. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract][Full Text] [Related]
12. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
[TBL] [Abstract][Full Text] [Related]
13. First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer.
Zarkar A; Henderson D; Carver A; Heyes G; Harrop V; Tutill S; Kilkenny J; Marshall A; Elbeltagi N; Howard H
BJUI Compass; 2023 Jul; 4(4):464-472. PubMed ID: 37334027
[TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.
Li M; Yang X; Chen Y; Yang X; Dai X; Sun F; Zhang L; Zhan C; Feng M; Wang Q
Onco Targets Ther; 2017; 10():2885-2892. PubMed ID: 28652770
[TBL] [Abstract][Full Text] [Related]
16. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
[TBL] [Abstract][Full Text] [Related]
19. Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.
Wade R; South E; Anwer S; Sharif-Hurst S; Harden M; Fulbright H; Hodgson R; Dias S; Simmonds M; Rowe I; Thornton P; Eastwood A
Health Technol Assess; 2023 Dec; 27(29):1-172. PubMed ID: 38149643
[TBL] [Abstract][Full Text] [Related]
20. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
